跳转至内容
Merck
CN

255165

三丁基甲基氯化铵 溶液

75 wt. % in H2O

别名:

甲基三丁基氯化铵 溶液

登录 查看组织和合同定价。

选择尺寸


关于此项目

线性分子式:
CH3N[CH3(CH2)3]3Cl
化学文摘社编号:
分子量:
235.84
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352116
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C13H30N.ClH/c1-5-8-11-14(4,12-9-6-2)13-10-7-3;/h5-13H2,1-4H3;1H/q+1;/p-1

SMILES string

[Cl-].CCCC[N+](C)(CCCC)CCCC

InChI key

IPILPUZVTYHGIL-UHFFFAOYSA-M

vapor pressure

7.9 mmHg ( 25 °C)

Quality Level

assay

77.2%

form

liquid

concentration

75 wt. % in H2O

refractive index

n20/D 1.4682

bp

152 °C

density

0.964 g/mL at 25 °C

General description

三丁基甲基氯化铵(TBMAC)是一种季铵盐,常用作各种有机合成反应的相转移催化剂。也用于制备离子液体。

Application

三丁基甲基氯化铵溶液可作为相转移催化剂,用于在KHSO5氧化剂存在下,经由环己酮的Baeyer-Villiger氧化反应合成ɛ-己内酯。

pictograms

Exclamation markEnvironment

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2

存储类别

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type ABEK (EN14387) respirator filter


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

New and efficient technique for the synthesis of ?-caprolactone using KHSO5 as an oxidising agent in the presence of a phase transfer catalyst
Baj S, et al.
Applied Catalysis A: General, 395(1-2), 49-52 (2011)
Enantioselective biocatalytic reduction of 2 H-1, 4-benzoxazines using imine reductases
Zumbra?gel N, et al.
The Journal of Organic Chemistry, 84(3), 1440-1447 (2018)
J W Smit et al.
The Journal of pharmacology and experimental therapeutics, 286(1), 321-327 (1998-07-10)
We recently showed that absence of mdr1-type P-glycoprotein (P-gp) in mice resulted in profoundly reduced hepatic and intestinal clearance of type 1 and type 2 cationic drugs compared with that in wild-type mice. These data strongly support the concept that
J W Smit et al.
British journal of pharmacology, 123(3), 361-370 (1998-03-21)
1. In the present study it was tested whether known P-glycoprotein (P-gp) substrates/MDR reversal agents interact with small (type 1) and bulky (type 2) cationic drugs at the level of biliary excretion in the rat isolated perfused liver model (IPRL).
Min-Koo Choi et al.
Journal of pharmaceutical sciences, 94(2), 317-326 (2004-12-01)
The in vivo canalicular excretion clearance of tributylmethyl ammonium (TBuMA), a P-glycoprotein (P-gp) substrate, was previously reported to be unaffected by the induction of an experimental hepatic injury (EHI) by CCl(4) despite the increased expression of P-gp in the EHI

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持